Search Page

1

Cite

Share

Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s.

Oba T, Long MD, Keler T, Marsh HC, Minderman H, Abrams SI, Liu S, Ito F. Oba T, et al. Among authors: keler t. Nat Commun. 2020 Oct 27;11(1):5415. doi: 10.1038/s41467-020-19192-z. Nat Commun. 2020. PMID: 33110069 Free PMC article.

Cite

Share

2

Cite

Share

High-Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization.

Alcántara-Hernández M, Leylek R, Wagar LE, Engleman EG, Keler T, Marinkovich MP, Davis MM, Nolan GP, Idoyaga J. Alcántara-Hernández M, et al. Among authors: keler t. Immunity. 2017 Dec 19;47(6):1037-1050.e6. doi: 10.1016/j.immuni.2017.11.001. Epub 2017 Dec 5. Immunity. 2017. PMID: 29221729 Free PMC article.

Cite

Share

3

Cite

Share

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT IV trial investigators. Weller M, et al. Among authors: keler t. Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23. Lancet Oncol. 2017. PMID: 28844499 Free article. Clinical Trial.

Cite

Share

4

Cite

Share

Antibody-targeted vaccines.

Keler T, He L, Ramakrishna V, Champion B. Keler T, et al. Oncogene. 2007 May 28;26(25):3758-67. doi: 10.1038/sj.onc.1210375. Oncogene. 2007. PMID: 17530028 Review.

Cite

Share

5

Cite

Share

Mannose receptor-targeted vaccines.

Keler T, Ramakrishna V, Fanger MW. Keler T, et al. Expert Opin Biol Ther. 2004 Dec;4(12):1953-62. doi: 10.1517/14712598.4.12.1953. Expert Opin Biol Ther. 2004. PMID: 15571457 Review.

Cite

Share

6

Cite

Share

Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity.

Trumpfheller C, Longhi MP, Caskey M, Idoyaga J, Bozzacco L, Keler T, Schlesinger SJ, Steinman RM. Trumpfheller C, et al. Among authors: keler t. J Intern Med. 2012 Feb;271(2):183-92. doi: 10.1111/j.1365-2796.2011.02496.x. Epub 2012 Jan 4. J Intern Med. 2012. PMID: 22126373 Free PMC article. Review.

Cite

Share

7

Cite

Share

Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab.

Ramakrishna V, Sundarapandiyan K, Zhao B, Bylesjo M, Marsh HC, Keler T. Ramakrishna V, et al. Among authors: keler t. J Immunother Cancer. 2015 Aug 18;3:37. doi: 10.1186/s40425-015-0080-2. eCollection 2015. J Immunother Cancer. 2015. PMID: 26500773 Free PMC article.

Cite

Share

8

Cite

Share

Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.

Korman A, Yellin M, Keler T. Korman A, et al. Among authors: keler t. Curr Opin Investig Drugs. 2005 Jun;6(6):582-91. Curr Opin Investig Drugs. 2005. PMID: 15988909 Review.

Cite

Share

9

Cite

Share

Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.

Vitale LA, Thomas LJ, He LZ, O'Neill T, Widger J, Crocker A, Sundarapandiyan K, Storey JR, Forsberg EM, Weidlick J, Baronas AR, Gergel LE, Boyer JM, Sisson C, Goldstein J, Marsh HC Jr, Keler T. Vitale LA, et al. Among authors: keler t. Cancer Immunol Immunother. 2019 Feb;68(2):233-245. doi: 10.1007/s00262-018-2267-0. Epub 2018 Oct 31. Cancer Immunol Immunother. 2019. PMID: 30382327

Cite

Share

10

Cite

Share

CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.

Morse MA, Bradley DA, Keler T, Laliberte RJ, Green JA, Davis TA, Inman BA. Morse MA, et al. Among authors: keler t. Expert Rev Vaccines. 2011 Jun;10(6):733-42. doi: 10.1586/erv.11.20. Expert Rev Vaccines. 2011. PMID: 21692696 Review.

Cite

Share